Cargando…
Immunotherapy in Malignant Pleural Mesothelioma
The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most important immunotherapy-based resea...
Autores principales: | de Gooijer, Cornedine J., Borm, Frank J., Scherpereel, Arnaud, Baas, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047444/ https://www.ncbi.nlm.nih.gov/pubmed/32154179 http://dx.doi.org/10.3389/fonc.2020.00187 |
Ejemplares similares
-
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020) -
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020) -
Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022) -
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021) -
Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
por: Choi, Agnes Y., et al.
Publicado: (2022)